Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RenascienceTSE:4889 -1.13%47 EV-to-EBITDA is -41.63 as of Sep. 03, 2026. GuruFocus rates TSE:4889 with a GF Score™ of 47/100 and a GF Value™ of 円305.30 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 514 Medical Devices & Instruments companies, Renascience ranks worse than 194552.33% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Renascience's enterprise value is 円14,016.05 Mil.
Renascience's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円-336.71 Mil. Therefore, Renascience's EV-to-EBITDA for today is -41.63.
The historical rank and industry rank for Renascience's EV-to-EBITDA or its related term are showing as below:
TSE:4889'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -204.52 Med: -15.72 Max: -5.71
Current: -41.62
During the past 7 years, the highest EV-to-EBITDA of Renascience was -5.71. The lowest was -204.52. And the median was -15.72.
TSE:4889's EV-to-EBITDA is ranked worse than 100% of 514
companies
in the Medical Devices & Instruments industry
Industry Median: 14.355
vs TSE:4889: -41.62
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Renascience's PE Ratio (TTM) for today is calculated as:
Renascience's share price for today is 円1135.00.
Renascience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-24.080.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Renascience's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4889 vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Renascience's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Renascience EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Renascience's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Renascience's EV-to-EBITDA falls into.
Renascience's current Enterprise Value is 円14,016.05 Mil.
Renascience's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-336.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Renascience (TSE:4889) has a EV-to-EBITDA of -41.63 as of Sep. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Renascience. According to the industry distribution chart, Renascience ranks #999999 out of 514 companies in the Medical Devices & Instruments industry.
Is Renascience's EV-to-EBITDA too high?
Renascience's current EV-to-EBITDA is -41.63. Based on the distribution chart, Renascience ranks #999999 out of 514 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Renascience has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Renascience's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Renascience ranks #999999 out of 514 companies for EV-to-EBITDA. This places Renascience in the lower half of its industry. The industry median EV-to-EBITDA is 14.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.36, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Renascience. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Renascience's current EV-to-EBITDA is -41.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renascience stock overvalued right now?
Based on GuruFocus' analysis, Renascience (TSE:4889) is currently considered Significantly Overvalued. The stock's GF Value™ is 円305.30, compared to a current price of 円1,135.00 — trading 271.8% above its estimated fair value. The current EV-to-EBITDA is -41.63. Renascience's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Renascience (TSE:4889), the current EV-to-EBITDA is -41.63 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Renascience (TSE:4889) Overvalued in 2026?
Based on GuruFocus' analysis, Renascience stock appears to be overvalued.
The current stock price of 円1,135.00 is trading 271.8% above its estimated GF Value™ of 円305.30.
GuruFocus considers Renascience to be Significantly Overvalued.
Key valuation signals for TSE:4889:
EV-to-EBITDA: -41.63
GF Value™: 円305.30 vs. price of 円1,135.00 (271.8% above fair value)
No single metric tells the full story. See the TSE:4889 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Renascience Inc is engaged in the Development and commercialization of pharmaceuticals, medical devices, pieces of software as a medical device (SaMD) utilizing AI, etc.
47GF Score
Get the complete analysis for TSE:4889
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4889 has been successfully added to your 
